Effects of autacoid inhibitors and of an antagonist on malaria infection in mice.
The effects of p-chlorophenylalanine, an inhibitor of serotonin synthesis, indomethacin, an inhibitor of prostaglandin synthesis, cyproheptadine, a serotonin, bradykinin and histamine antagonist, were assessed separately and in combination with chloroquine (CQ) in Vom strains of Swiss albino mice (18-22 g) of either sex infected intraperitoneally with 1 x 10(7) Plasmodium yoelii nigeriensis-induced malaria. As prophylactic, these agents reduced from 31.9 +/- 4.5 to 16.1 +/- 8.1% the level of parasitemia relative to control but had no appreciable activity as curative agents when administered subcutaneously once daily for 4 days after 72 h of parasites innoculum in vivo. However, CQ alone and the combination of these agents with CQ in curative and prophylactic treatments significantly reduced (from 50.3 +/- 5.8 to 4.9 +/- 0.75%) the level of parasitemia (P < 0.05), which was taken only once 72 h after the parasites innoculum. The prophylactic result was shown to produce better results than the curative treatment. The data indicate that inhibitors and an antagonist can reduce the parasitemia load (the extent of damage and the severity of infection) as well as enhance the effects of CQ when combined with it for malaria therapy. The study reveals that the production of autacoids in established infection renders autacoid inhibitors and an antagonist ineffective for radical cure in malarial mice; however, selective inhibition of local hormones implicated in the pathological manifestations of malaria infection by autacoid inhibitors and an antagonist may be a possible pathway to reduce the severity of infection and the associated tissue damage and to enhance the efficacy of available anti-malarials.
Iwalewa
E O
EO
Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. eoiwalewa@yahoo.com
Agbani
E O
EO
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D012898:Autacoids / Q000037:antagonists & inhibitors*; D002738:Chloroquine / Q000627:therapeutic use; D003533:Cyproheptadine / Q000627:therapeutic use; D004338:Drug Combinations; D010134:Fenclonine / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D018512:Parasitemia / Q000188:drug therapy; D012702:Serotonin Antagonists / Q000627:therapeutic use
D000962:Antimalarials; D012898:Autacoids; D004338:Drug Combinations; D006633:Histamine Antagonists; D012702:Serotonin Antagonists; D003533:Cyproheptadine; D002738:Chloroquine; D010134:Fenclonine; D007213:Indomethacin